重组人血管内皮抑制素联合铂类方案化疗治疗晚期非小细胞肺癌临床观察

Clinical observation of recombinant human endostatin combined with platinum-based chemotherapy in treatment of advanced non-small cell lung cancer

目的探讨重组人血管内皮抑制素联合铂类方案化疗治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 78例晚期NSCLC患者随机均分为两组,观察组39例患者接受重组人血管内皮抑制素联合铂类方案化疗治疗,而对照组39例患者仅接受铂类方案化疗。治疗后评价两组患者的疗效及毒副反应。结果观察组患者总有效率为41.03%,高于对照组的17.95%(χ2=4.994,P=0.025);观察组患者临床获益率为84.62%,高于对照组的64.10%(χ2=4.303,P=0.038)。观察组生活质量改善率与对照组相似(χ2=2.776,P=0.096)。两组毒副反应相似,且均可耐受。结论重组人血管内皮抑制素联合铂类方案化疗治疗晚期NSCLC安全有效。

Objective To study the efficacy and safety of recombinant human endostatin combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods All of 78 patients with advanced NSCLC were randomly divided into two groups,39 patients of the observer group received the recombinant human endostatin combined with platinum-based chemotherapy,39 patients of the control group only received platinum-based chemotherapy.The efficacy and toxicities of the two groups were evaluated comparatively. Results The total effective rate of the observation group （41.03%） was higher than that of the control group （17.95%） （χ2=4.994,P = 0.025）; the clinical benefit rate of the observation group （84.62%） was higher than that of the control group （64.10%） （χ2=4.303,P = 0.038）; The improvement rate of quality of life of the observation group was similar to that of the control group （χ2=2.776,P = 0.096）. The toxicities of two groups could be tolerated. Conclusion Recombinant human endostatin combined with platinum-based chemotherapy is safe and effective for advanced NSCLC.